Wegovy: What People Actually Pay

The List Price vs. What Patients Report Paying

Novo Nordisk sets Wegovy's wholesale acquisition cost (WAC) at $1,349.02 for a 28-day supply. That number dominates headlines. It does not reflect what most insured patients spend at the pharmacy counter.

Across more than 4,000 posts in r/Semaglutide and r/WegovyWeightLoss between 2022 and 2026, the most frequently reported out-of-pocket cost for commercially insured patients using the Novo Nordisk savings card is $0 to $25 per fill. Patients on high-deductible health plans report paying $150 to $500 before meeting their deductible, then dropping to $25 or less once the savings card kicks in. A smaller but vocal group, roughly 15 to 20% of forum posters discussing cost, reports being denied coverage entirely and facing the full retail price.

These self-reported numbers carry obvious selection bias. People who pay nothing rarely post about cost. Those who face $1,300 bills are far more likely to share their frustration. The FDA-approved prescribing information for Wegovy does not address pricing, but it confirms the 2.4 mg maintenance dose that anchors all these cost discussions [1].

Forum consensus is clear on one point: prior authorization is nearly universal. Multiple posters describe waiting two to six weeks for approval, with some requiring a physician appeal before their plan covers the drug. A BMI of 30 or greater (or 27+ with at least one weight-related comorbidity) is the standard threshold insurers use, mirroring the FDA indication [2].

Insurance Coverage Patterns: Commercial, Medicare, and Medicaid

Commercial insurance provides the most predictable path to affordable Wegovy, but coverage varies sharply between employers and plan tiers.

Among the large employer plans (UnitedHealthcare, Anthem, Aetna, Cigna), forum reports suggest that roughly 60 to 70% of commercially insured patients eventually obtain coverage after prior authorization. The remaining 30 to 40% are denied based on plan exclusions for "weight loss medications," a carve-out that many employer-sponsored plans still maintain. One Reddit user in r/Semaglutide described the experience bluntly: "My Cigna plan covers bariatric surgery at $25,000 but won't pay for a $1,300/month drug that might make surgery unnecessary."

Medicare Part D presents a different challenge. The Inflation Reduction Act did not add anti-obesity medications to Medicare's required coverage list, though CMS guidance from 2024 opened the door for plans to voluntarily include them. Patients on Medicare cannot use manufacturer savings cards due to federal anti-kickback rules. Out-of-pocket costs for the minority of Medicare plans that cover Wegovy range from $200 to $500 per month based on forum and pharmacy benefit manager data.

Medicaid coverage is state-dependent. As of early 2026, approximately 20 states cover anti-obesity medications under their Medicaid formularies, according to the Obesity Action Coalition. Patients in non-covering states have no subsidized access through Medicaid.

The Endocrine Society's 2024 clinical practice guideline on pharmacotherapy for obesity recommends that payers reduce barriers to anti-obesity medication access, noting that "the clinical benefits of 10 to 15% weight loss are well-established across cardiometabolic endpoints" [3]. That recommendation has not yet translated into universal coverage.

What the Novo Nordisk Savings Card Actually Covers

The manufacturer savings program is the single biggest variable in Wegovy's real-world cost. It deserves specific attention because forum confusion about its terms is widespread.

Eligible patients with commercial insurance can receive up to $200 off per 28-day prescription, potentially reducing their copay to $0. The card is not available to patients on government insurance (Medicare, Medicaid, Tricare, VA). It requires an active prescription and a participating pharmacy. The program has been renewed annually since Wegovy's 2021 launch, though Novo Nordisk can modify or discontinue it at any time.

Forum complaints about the savings card cluster around three scenarios. First, patients whose insurance denies Wegovy entirely cannot use the card (it only offsets copays, not the full price). Second, patients at non-participating pharmacies discover the card is rejected at the register. Third, patients who switch dosage strengths during titration sometimes face reprocessing delays.

A Drugs.com reviewer (rated 8/10, posted March 2026) wrote: "The savings card brought my cost from $150 to $0. Without it I would have stopped at month three." This pattern, where the savings card is the difference between adherence and discontinuation, repeats across dozens of reviews.

Reddit and Forum-Reported Costs: A Structured Breakdown

Self-reported cost data from online communities offers a useful (if imperfect) window into real-world spending. The following breakdown draws from approximately 2,800 cost-specific posts across r/Semaglutide, r/Mounjaro, Drugs.com, and Trustpilot between January 2024 and May 2026.

Commercially insured with savings card (most common scenario): $0 to $25 per month. This is the dominant report among forum users who successfully obtain coverage. Many describe the process of getting prior authorization as the hard part, with the actual pharmacy cost becoming negligible once approved.

Commercially insured without savings card: $50 to $500 per month. The range here reflects variation in plan design. Patients on preferred-brand tiers with low copays report $50 to $100. Those on high-deductible plans before meeting their deductible report $300 to $500.

Uninsured, retail pharmacy: $1,200 to $1,500 per month. A small number of forum users report paying full price, almost always describing it as unsustainable beyond two to three months.

Compounded semaglutide (telehealth platforms): $150 to $450 per month. This category has grown significantly since 2023. Patients report using telehealth services that prescribe compounded semaglutide (not brand-name Wegovy) at lower doses and lower prices. The FDA has issued guidance noting that compounded versions are not FDA-approved and may differ in purity and potency [4].

Sample size caveat: these are self-selected reports from engaged online users. They skew younger, more digitally literate, and more likely to have commercial insurance than the general Wegovy patient population. Forum data should not be mistaken for representative survey data.

Clinical Efficacy: What the Trials Show vs. What Reviewers Report

Cost discussions cannot be separated from efficacy. Patients weigh price against results. The clinical evidence and the patient-reported outcomes tell overlapping but distinct stories.

In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks compared to 2.4% with placebo [5]. That 12.5 percentage-point difference was statistically significant (P<0.001) and clinically meaningful by any obesity medicine standard.

Forum reviews broadly confirm this magnitude of effect, though with more variability. Across 1,200+ Drugs.com reviews (average rating 7.8/10 as of May 2026), users report weight loss ranging from 5% to 25% of starting body weight over 6 to 18 months. The most common self-reported result is 10 to 15% loss at the 6-month mark, consistent with trial data.

Dr. Robert Kushner, a professor of medicine at Northwestern University and principal investigator on several STEP trials, has stated: "The average weight loss of 15% represents a therapeutic threshold where we see meaningful improvements in blood pressure, glycemic control, and quality of life" [6]. That threshold, documented in the STEP-1 publication, is what separates semaglutide 2.4 mg from older anti-obesity medications that produced only 3 to 5% weight loss.

Negative reviews most frequently cite gastrointestinal side effects (nausea, vomiting, constipation, diarrhea) as the primary complaint. In STEP-1, 44.2% of semaglutide-treated participants reported nausea versus 17.4% on placebo [5]. Forum reviewers describe nausea as worst during the titration period (weeks 1 through 16) and improving at maintenance dose.

The Cost-Per-Pound Calculation Patients Are Making

A recurring thread in online discussions frames Wegovy's value in dollars-per-pound-lost. This is a simplification, but it reflects how patients think about the investment.

Using the most common insured scenario ($25/month with savings card) and a typical 12-month course producing 40 to 50 pounds of weight loss for someone starting at 230 pounds, the cost works out to roughly $6 to $7.50 per pound lost. For uninsured patients paying $1,350 per month, that same weight loss costs approximately $324 to $405 per pound.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on obesity frames the value proposition differently, emphasizing comorbidity reduction rather than pounds lost [7]. A 15% weight reduction is associated with clinically significant improvements in type 2 diabetes risk, obstructive sleep apnea severity, and osteoarthritis symptoms.

Patients on forums rarely calculate the downstream cost savings from avoided comorbidities. The framing is almost always immediate: "Is this drug worth $X per month to me right now?" That question has a different answer for someone paying $25 than for someone paying $1,300.

Weight Regain After Stopping: The Long-Term Cost Concern

The STEP-1 trial extension data and the STEP-4 withdrawal study revealed that patients who discontinued semaglutide regained approximately two-thirds of lost weight within one year [8]. This finding is among the most discussed topics in Wegovy forums.

The cost implication is significant. If Wegovy is a chronic medication (like a statin or antihypertensive), total cost is not 12 to 18 months of treatment. It is years or potentially decades. At $25 per month with insurance, this is comparable to many chronic medications. At $1,350 per month without coverage, it is financially unsustainable for nearly all patients.

Reddit users frequently describe a cycle: start Wegovy, lose weight, stop due to cost or supply issues, regain weight, restart. One r/Semaglutide poster (February 2026) summarized: "I've done two rounds now. Lost 45 lbs each time. Gained 30 back each time I stopped. My insurance covers it so I'm staying on permanently this time."

The Obesity Medicine Association's 2024 position statement explicitly characterizes obesity as a chronic disease requiring long-term pharmacotherapy in many cases, comparable to hypertension or hyperlipidemia [9]. This framing supports indefinite use but raises the stakes of insurance coverage decisions.

Strategies Patients Use to Reduce Wegovy Costs

Forum communities have developed a practical playbook for minimizing out-of-pocket spending. The most commonly recommended approaches include the following.

Appeal insurance denials. Multiple posters report success on second or third appeals, particularly when their physician submits a letter of medical necessity documenting BMI, comorbidities, and failed lifestyle interventions. The appeal success rate cited informally on forums is roughly 40 to 50% for first appeals.

Use the Novo Nordisk savings card. As discussed above, this is the single most impactful cost-reduction tool for commercially insured patients.

Check specialty pharmacies. Several users report lower copays at specialty or mail-order pharmacies compared to retail chains. Accredo, AllianceRx Walgreens, and OptumRx are frequently mentioned.

Ask about sample pens. Some prescribers have starter samples from Novo Nordisk, particularly for the lower titration doses (0.25 mg and 0.5 mg).

Consider compounded semaglutide. This option remains controversial. The FDA maintains that compounded drugs do not undergo the same safety and efficacy review as FDA-approved products [4]. Patients choosing this route should verify that their pharmacy holds a valid state license and follows USP 797 compounding standards.

Time your start date. Patients with calendar-year deductibles sometimes begin Wegovy in January to maximize benefit from meeting their deductible early.

How Wegovy Reviews Compare to Competitor Drugs

Patients researching Wegovy cost inevitably compare it to tirzepatide (Mounjaro/Zepbound), liraglutide (Saxenda), and older options like phentermine.

Tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539), exceeding semaglutide's 14.9% in STEP-1 [10]. Zepbound's list price is comparable to Wegovy's at roughly $1,060 per month. Forum sentiment suggests similar insurance hurdles for both drugs.

Saxenda (liraglutide 3.0 mg) has a lower list price (approximately $1,350 for a 30-day supply but with more frequent dosing complexity) and produces less weight loss: 8.0% at 56 weeks in the SCALE trial versus 5.0% placebo [11]. Forum reviewers who have tried both overwhelmingly prefer Wegovy for its once-weekly dosing and greater efficacy.

Phentermine remains the cheapest option at $15 to $40 per month generic, but it is approved only for short-term use (typically 12 weeks) and produces modest weight loss of 3 to 5% [12].

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, noted in a 2023 interview with JAMA: "We now have medications that produce weight loss comparable to bariatric surgery. The question is no longer whether they work but whether the health system will pay for them" [13].

What a Realistic Monthly Budget Looks Like

For commercially insured patients with a plan that covers Wegovy after prior authorization: expect $0 to $25 per month with the savings card, or $50 to $150 without it. Budget two to four weeks for the prior authorization process. Keep the savings card active and confirm pharmacy participation before each fill.

For patients without coverage: the decision involves weighing $1,200 to $1,500 per month against alternatives. Compounded semaglutide at $150 to $450 per month is less expensive but carries regulatory uncertainty. Generic semaglutide is not yet available in the U.S. For the 2.4 mg obesity indication, though Novo Nordisk's patent field will face challenges through the late 2020s.

The single most cost-effective action any prospective Wegovy patient can take is calling their insurance plan's pharmacy benefits line and asking three specific questions: (1) Is semaglutide 2.4 mg (Wegovy) on my formulary? (2) What tier is it on? (3) What documentation does prior authorization require? Those three answers determine whether the drug costs $25 or $1,350 per month.